Atherosclerotic Cardiovascular Disease

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

Santreva-ATK, the first wire-free endovascular revascularization catheter for crossing chronic total occlusions, is expected to begin sale in October 2025.

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.

Amgen announced that evolocumab reduced the risk of MACEs such as heart attack and stroke in patients without any prior history of these events.

Investigators have highlighted diabetes and obesity as leading drivers of steadily increasing global cardiovascular mortality rates.

Less than optimal outcomes with ASCVD also increased healthcare resource utilization and costs.

Despite prior trials indicating the possibility, the AUSPICE study failed to display any difference in risk between patients receiving the vaccine versus placebo.

Findings from an analysis of GBD 2021 data highlight increases in the absolute number of ASCVD cases and deaths among the working-age population.

Although PREVENT was more consistent among the overall population, PCE saw more accurate readings in those taking statins within the trial period.

Research shows reduced risk of death, major adverse cardiovascular events, and myocardial infarction, and a non-significant reduction in stroke and cardiovascular death.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.

The 2025 Concise Clinical Guidance also aims to assuage vaccine hesitancy and resistance, provide better education, and overcome barriers to implementation.

A recent analysis utilizing the AHA’s PREVENT equations has found 11.8 million US adults aged 40 to 75 had a 10-year ASCVD risk of 5% or greater.

Preliminary findings have also indicated an association between an evolocumab add-on to statin therapy and stenosis degree reduction.

New research shines a light on the liver’s role in cardiovascular disease prevention, indicating a potential new predictor for coronary heart disease.

Healthcare costs and resource utilization were significantly greater in individuals with ASCVD and CKD with systemic inflammation versus those without.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to discuss the results of this groundbreaking trial.

Hosts offer perspective on the topline results from SURPASS-CVOT and what the cardiovascular data on tirzepatide means for care.

Tirzepatide was non-inferior to dulaglutide with an 8% lower rate of MACE-3 events while delivering greater reductions in A1C and weight.

New research highlights significant declines in cardiovascular screenings for U.S. adults with disabilities during the COVID-19 pandemic, revealing ongoing healthcare disparities.